- Home
- TCBX vs BCYC Comparison
TCBX vs BCYC Comparison
Compare TCBX & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCBX | BCYC |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.8M | 476.6M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TCBX | BCYC |
|---|---|---|
| Price | $39.15 | $6.78 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $41.67 | $18.73 |
| AVG Volume (30 Days) | 68.4K | ★ 247.3K |
| Earning Date | 01-21-2026 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.90 | N/A |
| EPS | ★ 3.56 | N/A |
| Revenue | ★ $192,224,000.00 | $28,339,000.00 |
| Revenue This Year | $24.66 | N/A |
| Revenue Next Year | $17.56 | N/A |
| P/E Ratio | $10.90 | ★ N/A |
| Revenue Growth | ★ 20.96 | N/A |
| 52 Week Low | $25.17 | $6.03 |
| 52 Week High | $41.70 | $15.47 |
Technical Indicators
Market Signals| Indicator | TCBX | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 48.43 | 44.51 |
| Support Level | $39.28 | $6.73 |
| Resistance Level | $41.70 | $7.28 |
| Average True Range (ATR) | 1.06 | 0.33 |
| MACD | -0.15 | -0.04 |
| Stochastic Oscillator | 21.51 | 5.44 |
Price Performance
Historical ComparisonAbout TCBX Third Coast Bancshares Inc.
Third Coast Bancshares Inc is a bank holding company. It focuses on providing commercial banking solutions to small and medium-sized businesses and professionals with operations in its markets. The bank operates eleven branches in the Greater Houston, Dallas-Fort Worth, and Austin-San Antonio markets, and one branch in Detroit, Texas. The company operates through one segment, community banking, It generates the majority of its revenue from interest on loans, customer service, and loan fees.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.